This case report highlights the fatal risk of Neuroleptic Malignant Syndrome when using haloperidol and phenelzine in patients with severe liver impairment.
Answers are grounded in this paper and cite their sources.
May signal fatal NMS risk with haloperidol-phenelzine in severe liver impairment; hypothesis-generating case report needing confirmation.
A fatal case of Neuroleptic Malignant Syndrome (NMS) affecting a middle-aged woman is presented. Most of the signs and symptoms described for NMS were present and death occurred three hours after the onset of hyperpyrexia. Laboratory and postmortem findings were non-specific. The uses and risks of Haloperidol and Phenelzine on a patient with severe liver impairment are considered. Finally, the medico-legal implications in the context of sudden unexpected death are mentioned.
No takes yet. Share an insight, caveat, or question.
Lannas et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: